Latest Replikins Ltd. Stories
LONDON, June 20, 2011 /PRNewswire/ -- Scientists Drs. Samuel and Elenore Bogoch of BioRadar UK Ltd. announced that retrospective studies indicate that an increase in Replikin Counts of the EHEC lethal strains of E. Coli preceded the current E. Coli outbreak. These EHEC strains of E. Coli have been studied in laboratories in Germany and elsewhere since 1995, and genome sequences are consequently available in the public databases. Replikins are subsequences of the genome of an infectious...
BOSTON, Nov. 25 /PRNewswire/ -- Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus. The new data shows that the lethality of the H1N1 ("Swine Flu") virus has dropped from its peak of 3.7 (s.d. 4.5) during the virus's current outbreak in the spring of 2009 to resting non-epidemic levels this week of 2.0 (s.d....
BOSTON, Oct. 19 /PRNewswire/ -- There is increasing evidence that, with best intent, current biological technology cannot supply the world's six billion humans, and animal populations, with vaccines against emerging diseases at a rate that can contend with a disease's rapid appearance and change, e.g., before the disease has come and gone. In view of Replikins Ltd.'s demonstration that Replikins(TM) chemically synthesized vaccines produced in seven days can be effective, the company today...
Boston Biotech Firm Reports First Rise in 76 Years of Replikin Count* of H1N1 Lethality Gene BOSTON, June 10 /PRNewswire/ -- An analysis of the latest peptide genomic data for the H1N1 influenza virus indicates that the current global outbreak of H1N1 is increasing in its capacity for lethality. The new sequence data on PubMed of the past two weeks through June 10, 2009 showed an increase in the Replikin Count* of the Replikin Lethality Gene in the pB1 genomic area from a mean of 2+/-0.2...
BOSTON, May 23 /PRNewswire/ -- Amid all the speculation over what course the Swine Flu epidemic will take, Boston-based biotech firm Replikins Ltd. (www.replikins.com) last week analyzed the most recent peptide genomic sequence data available and determined that the infectivity of the H1N1 virus will increase markedly, while its lethality will remain relatively low for the immediate future. The company's quantitative analysis of the most recent sequence data available on PubMed, a standard...
LONDON, May 4 /PRNewswire/ -- A synthetic peptide H1N1 vaccine is available now for testing worldwide, from Replikins Ltd. The company has developed the vaccine based on the same Replikins peptide technology which provided the surprise advance warning one year ago that the current H1N1 outbreak/pandemic was on its way (http://www.replikins.com). A unique advantage of the Replikins vaccine is its rapid availability; the WHO, CDC and others have stated that conventionally developed H1N1...
BOSTON, April 27 /PRNewswire/ -- Replikins Ltd. published a FluForecast(R) warning in April 7th, 2008, a year before the recent Mexico and California H1N1 cases. The company was able to state the likelihood of H1N1 outbreaks based on its patented Replikin Count(TM) genomics technology, which examines specific regions in virus genes which have been linked with past epidemics. The April 2008 announcement, attached below as published on the Web, stated that in H1N1 the company had then...
BOSTON, March 20 /PRNewswire/ -- Replikins, Ltd. announced today that data recently published from Harvard-CDC and Scripps-Crucell in Nature(1) and Science(2) confirms the 2001 discoveries by Dr. Samuel and Elenore Bogoch of peptides in the hemagglutinin unit of influenza, which they named Replikins, which are shared across flu strains, conserved over time, associated with the last three pandemics of 1918, 1957 and 1968, as well as current H5N1 outbreaks, and are the basis of broad spectrum...
BOSTON, Nov. 12 /PRNewswire/ -- WHO and CDC have stated that the predictive accuracy of their annual formulations for human influenza vaccines is "suboptimal" -- often correct less than 50% of the time, especially for seniors. Perhaps in part because we are not yet accurate in our predictions of upcoming influenza strains, approximately 36,000 people die each year of flu in the United States alone. As in the case of hurricanes, early warning of the location and intensity of...
